A phase I trial of two formulations of TKM HBV in healthy volunteers as a potential therapy for hepatitis B

Trial Profile

A phase I trial of two formulations of TKM HBV in healthy volunteers as a potential therapy for hepatitis B

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2016

At a glance

  • Drugs ARB 1467 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Arbutus Biopharma
  • Most Recent Events

    • 10 Jan 2016 Final results of this trial are expected in 1H16, as per Arbutus media release.
    • 10 Jan 2016 Status changed from recruiting to completed as per Arbutus media release.
    • 05 Aug 2015 According to an Arbutus Biopharma media release, the results from this trial are expected in the second half of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top